Human placental transfer of AH8165.
The human placental transfer of AH8165 (0times50times9 mg/kg) was studied in ten patients undergoing elective Caesarean section. There was no adverse effect on foetal movement attributable to placental transfer of the neuromuscular blocking drug. Bioassay of umbilical vein blood indicated that little AH8165 crossed the placenta. Studies using 3HAH8165 in two patients undergoing termination hysterectomy demonstrated transfer of only minute amounts of radioactivity to the foetus.
D001034:Apgar Score; D001391:Azo Compounds / Q000378:metabolism*; D001681:Biological Assay; D004717:Endometrium / Q000032:analysis; D005260:Female; D005333:Fetus / Q000032:analysis; D006801:Humans; D007044:Hysterectomy; D007093:Imidazoles / Q000378:metabolism; D008099:Liver / Q000032:analysis; D008431:Maternal-Fetal Exchange; D009132:Muscles / Q000032:analysis; D009466:Neuromuscular Blocking Agents / Q000097:blood / Q000378:metabolism*; D010920:Placenta / Q000032:analysis / Q000378:metabolism*; D011247:Pregnancy; D011726:Pyridinium Compounds / Q000378:metabolism*; D014316:Tritium / Q000378:metabolism; D014470:Umbilical Cord
D001391:Azo Compounds; D007093:Imidazoles; D009466:Neuromuscular Blocking Agents; D011726:Pyridinium Compounds; D014316:Tritium